UDP-Glucuronosyltransferase 1A10: Activity against the Tobacco-Specific Nitrosamine, 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a Potential Role for a Novel UGT1A10 Promoter Deletion Polymorphism in Cancer Susceptibility
Authors:
- Gang ChenGCGang Chen
- Ryan W. DellingerRDRyan W. Dellinger
- Philip LazarusPLPhilip Lazarus
- 1 March 2010
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 38 (3) , 484-490
Abstract
The extrahepatic UDP-glucuronosyltransferase 1A10 (UGT1A10) is a phase II metabolizing enzyme that is active against a number of potent carcinogens. In the present study, UGT1A10 was examined for activity against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), the major procarcinogenic metabolite of the potent tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, and the promoter region of UGT1A10 was examined for variants that could lead to altered UGT1A10 expression. UGT1A10-overexpressing cell homogenates exhibited high O-glucuronidation activity against NNAL (KM = 5.95 mM). A 2000-base pair (bp) product corresponding to the UGT1A10 proximal promoter region was polymerase chain reaction (PCR)-amplified using genomic DNA from 97 white subjects, and 42 of these were sequenced. In addition to a previously reported C/G single-nucleotide polymorphism at −1271 bp (rs2741032), a novel 1664-bp deletion located between nucleotides −190 to −1856 relative to the UGT1A10 translation start site was identified. Using real-time multiplex PCR, this deletion exhibited a prevalence of 0.022 in whites (n = 156) and 0.056 in blacks (n = 133). To determine whether either polymorphism altered gene expression, in vitro assays were performed using luciferase constructs containing up to 2000 bp of the proximal UGT1A10 promoter. Constructs containing the 1664-bp deletion exhibited a significant (p = 0.009) 3-fold increase in luciferase activity compared with constructs containing the wild-type UGT1A10 promoter. No effect on luciferase activity was observed for the UGT1A10−1271G promoter variant. These data are consistent with previous studies that indicate the presence of a transcriptional repressor element within the newly identified deletion and that this deletion polymorphism may contribute to altered UGT1A10 expression and altered carcinogen detoxification between individuals.Keywords
This publication has 38 references indexed in Scilit:
- Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell LinesDrug Metabolism and Disposition, 2008
- Glucuronidation of Tobacco-Specific Nitrosamines by UGT2B10Drug Metabolism and Disposition, 2008
- Critical Roles of Residues 36 and 40 in the Phenol and Tertiary Amine Aglycone Substrate Selectivities of UDP-Glucuronosyltransferases 1A3 and 1A4Molecular Pharmacology, 2007
- Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target geneSteroids, 2007
- IMPORTANCE OF UDP-GLUCURONOSYLTRANSFERASE 1A10 (UGT1A10) IN THE DETOXIFICATION OF POLYCYCLIC AROMATIC HYDROCARBONS: DECREASED GLUCURONIDATIVE ACTIVITY OF THE UGT1A10139LYS ISOFORMDrug Metabolism and Disposition, 2006
- Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma riskCancer, 2003
- Isolation and Characterization of the Human UGT2B7 GeneBiochemical and Biophysical Research Communications, 2000
- GlucuronidationGeneral Pharmacology: The Vascular System, 1998
- Isolation and Characterization of a Human Orphan UDP-Glucuronosyltransferase, UGT2B11Biochemical and Biophysical Research Communications, 1998
- Chromosomal Localization, Structure, and Regulation of the UGT2B17 Gene, Encoding a C19 Steroid Metabolizing EnzymeDNA and Cell Biology, 1997